Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.
Publication
, Conference
Badruddoja, MA; Reardon, DA; Akabani, G; Friedman, AH; Friedman, HS; Rich, JN; Quinn, JA; Penne, K; Vredenburgh, JJ; Bigner, DD
Published in: JOURNAL OF CLINICAL ONCOLOGY
July 15, 2004
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
July 15, 2004
Volume
22
Issue
14
Start / End Page
124S / 124S
Location
New Orleans, LA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
40th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Badruddoja, M. A., Reardon, D. A., Akabani, G., Friedman, A. H., Friedman, H. S., Rich, J. N., … Bigner, D. D. (2004). Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 22, pp. 124S-124S). New Orleans, LA: AMER SOC CLINICAL ONCOLOGY.
Badruddoja, M. A., D. A. Reardon, G. Akabani, A. H. Friedman, H. S. Friedman, J. N. Rich, J. A. Quinn, K. Penne, J. J. Vredenburgh, and D. D. Bigner. “Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.” In JOURNAL OF CLINICAL ONCOLOGY, 22:124S-124S. AMER SOC CLINICAL ONCOLOGY, 2004.
Badruddoja MA, Reardon DA, Akabani G, Friedman AH, Friedman HS, Rich JN, et al. Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 124S-124S.
Badruddoja, M. A., et al. “Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors.” JOURNAL OF CLINICAL ONCOLOGY, vol. 22, no. 14, AMER SOC CLINICAL ONCOLOGY, 2004, pp. 124S-124S.
Badruddoja MA, Reardon DA, Akabani G, Friedman AH, Friedman HS, Rich JN, Quinn JA, Penne K, Vredenburgh JJ, Bigner DD. Phase II trial of iodine 131-labeled murine anti-tenascin monoclonal anti-body 81C6 (M81C6) via surgically created resection cavity in the treatment of patients with recurrent malignant brain tumors. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2004. p. 124S-124S.
Published In
JOURNAL OF CLINICAL ONCOLOGY
ISSN
0732-183X
Publication Date
July 15, 2004
Volume
22
Issue
14
Start / End Page
124S / 124S
Location
New Orleans, LA
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
40th Annual Meeting of the American-Society-of-Clinical-Oncology
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences